Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in nonalcoholic steatohepatitis in rats

为了探讨血管紧张素II受体阻滞剂是否能预防NASH相关性肝细胞癌的发生发展，我们观察了ARB对胆碱缺乏L-氨基酸定义(CDAA)饮食NASH模型的影响。CDAA饮食24周后形成肝硬变，再摄入24周CDAA加重肝硬变，形成肝细胞癌。另一方面，替米沙坦，一种新型的ARB，即使在CDAA饮食喂养24周后，也能改善肝纤维化并防止肝癌的发生。这些发现表明，替米沙坦对NASH诱导的肝细胞癌具有治疗潜力，即使在肝纤维化形成之后也是如此。

To investigate whether angiotensin II receptor blocker could prevent the development of NASH related hepatocellular carcinoma (HCC), we examined the effect of ARB on choline-deficientL-aminoacid-defined (CDAA) diet NASH model. Twenty-four week-CDAA diet produced liver cirrhosis, and then CDAA diet for another 24 week aggravated liver cirrhosis, and produced HCC. On the other hand, telmisartan, a novel ARB, improved hepatic fibrosis and protected hepatic carcinogenesis even after 24-week CDAA diet feeding. These finding indicate that telmisartan has a therapeutic potential for NASH induced production of HCC even after hepatic fibrosis had been developed.